Skip to main content
. Author manuscript; available in PMC: 2022 Dec 9.
Published in final edited form as: J Hypertens. 2022 Aug 8;40(11):2111–2119. doi: 10.1097/HJH.0000000000003243

FIGURE 2.

FIGURE 2

Low-dose ketone supplementation could be a novel antihypertensive therapy by promoting endothelium-dependent vasodilation and proliferation. Exogenous supplementation is a means of bypassing endogenous ketogenesis, as interventions such as caloric restriction, ketogenic diets, and 1,3-butanediol all have concerns regarding their long-term utilization and/or efficacy at lowering blood pressure. Figure created by Biorender.com under license.